Endocyte, which is developing EC145 (entering Phase III) for the treatment of ovarian cancer, will see its quiet period end on Tuesday, March 15. On February 3, the company raised $75 million by offering 12.5 million shares at $6, below the range of $13 to $15....read more
After pricing 12.5 million shares at $6 late this morning, ovarian cancer drug developer Endocyte opened for trading mid-day, with the stock initially gaining 7%. Endocyte, which is developing a treatment for platinum-resistant ovarian cancer, had originally...read more
Endocyte, which is developing EC145 (entering Phase III) for the treatment of ovarian cancer, has modified terms again for its upcoming IPO on Friday. The West Lafayette, IN-based company now plans to raise $75 million by offering 12.5 million shares at an...read more
According to an amended SEC filing, ovarian cancer drug developer Endocyte doubled the number of shares to be offered in its IPO from 5.35 million to 10.7 million, while at the same time cutting the proposed price range in half, from $13-$15 to $7 per share. ...read more
Endocyte quiet period ends March 15
Endocyte, which is developing EC145 (entering Phase III) for the treatment of ovarian cancer, will see its quiet period end on Tuesday, March 15. On February 3, the company raised $75 million by offering 12.5 million shares at $6, below the range of $13 to $15....read more
With much delay, cancer drug developer Endocyte opens for trading
After pricing 12.5 million shares at $6 late this morning, ovarian cancer drug developer Endocyte opened for trading mid-day, with the stock initially gaining 7%. Endocyte, which is developing a treatment for platinum-resistant ovarian cancer, had originally...read more
Endocyte modifies IPO terms for the second time; drops estimated offer price to $6
Endocyte, which is developing EC145 (entering Phase III) for the treatment of ovarian cancer, has modified terms again for its upcoming IPO on Friday. The West Lafayette, IN-based company now plans to raise $75 million by offering 12.5 million shares at an...read more
Ovarian cancer drug developer Endocyte amends IPO terms
According to an amended SEC filing, ovarian cancer drug developer Endocyte doubled the number of shares to be offered in its IPO from 5.35 million to 10.7 million, while at the same time cutting the proposed price range in half, from $13-$15 to $7 per share. ...read more